Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
27 sept. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
CARGO Therapeutics Announces Appointment of Michael Ports, PhD, as Chief Scientific Officer
12 sept. 2023 09h05 HE
|
CARGO Therapeutics, Inc.
– Scientific leader with multi-company cell therapy drug development experience spanning early discovery initiatives through late-stage development – SAN MATEO, Calif., Sept. 12, 2023 (GLOBE...
Monthly information on share capital and company voting rights
05 sept. 2023 16h30 HE
|
Cellectis Inc.
PARIS, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of...
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood
05 sept. 2023 07h00 HE
|
Autolus Therapeutics plc
Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALLComplete responses observed in patients with CD19 negative disease No antigen negative relapse seen in...
CARGO Therapeutics Appoints Biotech Life Sciences Leaders to Board of Directors
24 août 2023 09h05 HE
|
CARGO Therapeutics, Inc.
– Board of Director appointments follow the Company’s recent launch and $200 million Series A financing in March 2023 – – Appointments include industry veterans John Orwin as Chairman, David Lubner...
Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy
16 août 2023 08h00 HE
|
Mustang Bio, Inc.
Initial data show clinical responses from four of four indolent lymphoma patients, including complete response in follicular lymphoma patient previously treated with CD19 CAR-T cell therapy Aligns...
Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
14 août 2023 16h05 HE
|
Mustang Bio, Inc.
WORCESTER, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
03 août 2023 16h30 HE
|
Cellectis Inc.
Updated clinical & translational data on BALLI-01 trial (evaluating UCART22 in r/r B-cell ALL) presented at the EHA annual meeting Clinical trials ongoing: BALLI-01 (evaluating UCART22),...
Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress
03 août 2023 07h00 HE
|
Autolus Therapeutics plc
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US...
Monthly information on share capital and company voting rights
01 août 2023 16h30 HE
|
Cellectis Inc.
PARIS, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...